Amexdrug Corporation
(Exact name of registrant as specified in its charter)

NEVADA	95-2251025
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer identification No.)

7251 Condor Street
Commerce, California 90040
(Address of principal executive offices) (Zip code)

Registrant's telephone number: (323) 725-3100

IR Contact
Jack Amin
7251 Condor Street
Commerce, CA 90040
(323) 725-3100

Trading Symbol: AXRX
CUSIP: 031139207
Par Value: $0.001
Total shares authorized: 1,000,000,000 as of **September 30, 2015**
Total shares outstanding: 169,409,620 as of **September 30, 2015**

Transfer Agent
Fidelity Transfer
8915 South 700 East
Salt Lake City, UT 84070
Tel: 801-562-1300
The Transfer Agent is registered under the Exchange Act.

There are no restrictions on the transfer of securities, and there have been no trading suspension orders issued by the SEC in the past 12 months.

Issuance History

In the past two years, the Company has not conducted any private placements of equity securities or convertible debt financing.

TABLE OF CONTENTS

Page

Item 3. Financial Statements (Unaudited)……..……...3

Condensed Consolidated Balance Sheets …….....4

Condensed Consolidated Statements of Operations ..……..……..…..5

Condensed Consolidated Statements of Cash Flows ……..……..……6

Notes to the Condensed Consolidated Financial Statements (Unaudited) ……..……..……7-8

Item 4. Business Segment Information……..……...…….9-10

Item 5. Identification of Directors and Executive Officers……...11

Item 6. Legal Proceedings…… 12

Item 7. Certifications…….13

Item 3. Financial Statements (Unaudited)

The consolidated balance sheets of Amexdrug Corporation, a Nevada corporation, and subsidiaries as of September 30, 2015, the related consolidated statements of operations for the three and nine months ended September 30, 2015 and 2014, the related condensed consolidated statements of cash flows for the three and nine months ended September 30, 2015 and 2014, and the notes to the condensed consolidated financial statements. The condensed consolidated financial statements have been prepared by Amexdrug's management.

The accompanying condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary to present fairly the results of operations and financial position of Amexdrug Corporation consolidated with BioRx Pharmaceuticals, Inc., Allied Med, Inc., and Dermagen, Inc., its wholly owned subsidiaries, and all such adjustments are of a normal recurring nature. The names "Amexdrug", "we", "our" and "us" used in this report refer to Amexdrug Corporation.

AMEXDRUG CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2015 (Unaudited)	December 31, 2014
Assets		
Current Assets		
Cash and cash equivalents	$ 392,406	$ 172,569
Investment	7,651	7,651
Accounts receivable, net of allowance of $48,111, respectively	754,541	452,524
Prepaid expenses	28,038	157,910
Inventory	517,218	459,219
Other asset	43,210	25,400
Deferred tax asset	25,400	36,374
Total Current Assets	1,768,464	1,311,647
Property and Equipment, at net	25,733	31,890
Other Assets		
Other deposits	29,862	29,862
Intangibles		
Customer base, net of accumulated amortization of $18,259	-	-
Trademark, net of accumulated amortization of $3,090 and $3,007, respectively	194	318
Goodwill	17,765	17,765
Total Other Assets	47,821	47,945
Total Assets	$ 1,842,018	$ 1,391,482
Liabilities and Shareholders' Equity		
Current Liabilities:		
Accounts payable and accrued expenses	$ 353,872	$ 198,121
Corporate tax payable	11,743	11,743
Notes payable related parties	108,023	108,023
Business lines and short term promissory note	-	292,990
Promissory note, current portion	-	68,544
Total Current Liabilities	473,638	679,421
Long Term Liabilities		
Promissory note	-	186,511
Total Long Term Liabilities	-	186,511
Total Liabilities	473,638	865,932
Shareholders' Equity		
Common stock, $0.0001 par value;		
1,000,000,000 authorized common shares		
169,409,620 shares issued and outstanding	169,410	169,410
Additional paid in capital	(77,594)	(77,594)
Treasury stock	(19,924)	(19,924)
Retained earnings	1,296,488	453,658
Total Shareholders' Equity	1,368,380	525,550
Total Liabilities and Shareholders' Equity	$ 1,842,018	$ 1,391,482

The accompanying notes are an integral part of these consolidated financial statements

AMEXDRUG CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

	Three Months Ended		Nine Months Ended	
	September 30, 2015	September 30, 2014	September 30, 2015	September 30, 2014
Sales	$ 2,143,218	$ 2,230,232	$ 7,213,354	$ 6,655,861
Cost of Goods Sold	1,889,632	1,997,873	5,672,739	5,478,226
Gross Profit	253,586	232,359	1,540,615	1,177,635
Operating Expenses				
Selling, general and administrative expense	222,251	209,470	677,464	732,328
Total Operating Expenses	222,251	209,470	677,464	732,328
Income before depreciation expense	31,335	22,889	863,151	445,307
Depreciation and amortization expense	1,977	2,697	7,081	8,091
Income before Other Income/(Expenses)	29,358	20,192	856,070	437,216
Other Income/(Expenses)				
Interest and other income	-	1	-	8
Penalty	-	-	-	(250)
Write off obsolete inventory	-	-	-	(9,543)
Unrealized gain/(loss)	-	-	-	(565)
Interest expense	(2,174)	(6,878)	(13,170)	(22,343)
Total Other Income/(Expenses)	(2,174)	(6,877)	(13,170)	(32,693)
Income before Provision for Income Taxes	27,184	13,315	842,900	404,523
Income tax (expense) benefit	-	(45,700)	-	(81,936)
Net Income	$ 27,184	$ (32,385)	$ 842,900	$ 322,587
BASIC AND DILUTED INCOME PER SHARE	$ 0.00	$ 0.00	$ 0.00	$ 0.00
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED	169,409,620	169,409,620	169,409,620	169,409,620

The accompanying notes are an integral part of these consolidated financial statements

AMEXDRUG CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

	Nine Months Ended	
	September 30, 2015	September 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net income	$ 842,900	322,587
Adjustment to reconcile net income to net cash used in operating activities		
Depreciation and amortization	7,081	8,091
Unrealized gain on investment	-	565
Cost associated with investment transactions	-	44
Change in Assets and Liabilities		
(Increase) Decrease in:		
Accounts receivable	(302,017)	(314,516)
Inventory	(57,999)	177,263
Prepaid expenses	129,872	191,935
Deferred tax asset	10,974	15,200
Other assets	(17,810)	(4,556)
Increase (Decrease) in:		
Accounts payable and accrued liabilities	155,751	97,321
Deferred operating lease liability	-	(2,399)
Deferred tax liability	-	29,900
Corporate income tax payable	-	41,242
NET CASH PROVIDED IN OPERATING ACTIVITIES	$ 768,752	562,677
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of investment	-	(2,836)
Purchase of fixed assets	(800)	(1,397)
NET CASH USED IN INVESTING ACTIVITIES	(800)	(4,233)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Purchase of treasury stock	-	(2,164)
Proceeds from loan payable	(255,055)	(47,829)
Payments on credit line	(292,990)	(248,800)
NET CASH USED BY FINANCING ACTIVITIES	(548,045)	(298,793)
NET INCREASE (DECREASE) IN CASH	219,907	259,651
CASH, BEGINNING OF PERIOD	172,499	74,730
CASH, END OF PERIOD	392,406	334,381
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION		
Interest paid	$ 7,429	$ 15,862
Income taxes	$ -	$ -

The accompanying notes are an integral part of these consolidated financial statements

AMEXDRUG CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANICAL STATEMENTS – (UNAUDITED)
SEPTEMBER 30, 2015

1. Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. For further information refer to the financial statements and footnotes thereto included in the Company's annual filing for the year ended December 31, 2014.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This summary of significant accounting policies of AmexDrug Corporation is presented to assist in understanding the Company's financial statements. The financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.

Income per Share Calculations

Income per Share dictates the calculation of basic earnings per share and diluted earnings per share. Basic earnings per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company's diluted income per share is the same as the basic income per share for the nine months ended September 30, 2015, because there are no outstanding dilutive instruments.

3. CAPITAL STOCK

At September 30, 2015, the Company's authorized stock consisted of 1,000,000,000 shares of common stock, with a par value of $0.001.

During the nine months ended September 30, 2015, the Company issued no shares of common stock.

4. INCOME TAXES

The Company files income tax returns in the U.S. Federal jurisdiction, and the state of California. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2013.

The Company accounts for uncertainty in tax positions by recognition in the financial statements.

The Company's policy is to recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.

5. BUSINESS SEGMENT INFORMATION

Beginning in 2005, the Company has operations in two segments of its business, namely: Distribution and Health and Beauty Products. Distribution consists of the wholesale pharmaceutical distribution and resale of brand and generic pharmaceutical products, over-the-counter drugs and non-drug products and health and beauty products. Health and Beauty Products consist of the manufacture and distribution of primarily health and beauty products.

The following tables describe information regarding the operations and assets of these reportable business segments:

	Distributions	Health and Beauty Products	Total
For the nine months ended September 30, 2015			
Sales to external customers	$ 4,950,084	$ 2,263,270	$ 7,213,354
Depreciation and amortization	$ 2,782	$ 4,299	$ 7,081
Segment income (loss) before taxes	$ 385,386	$ 457,514	$ 842,900
Segment assets	$ 930,155	$ 911,863	$ 1,842,018
For the nine months ended September 30, 2014			
Sales to external customers	$ 4,847,930	$ 1,807,931	$ 6,655,861
Depreciation and amortization	$ 2,820	$ 5,271	$ 8,091
Segment income (loss) before taxes	$ 196,621	$ 207,901	$ 404,522
Segment assets	$ 983,219	$ 788,403	$ 1,771,622

6. PROMISSORY NOTE

On June 9, 2013, the Company entered into a demand promissory note in the amount of $350,000, with a variable interest rate based on the index, which was currently 3.25% per annum at the time the note was signed. At the lenders discretion the note must be paid in full upon demand. If no demand is made, the note will be paid in sixty (60) monthly payments of $6,698. The first payment is due July 9, 2013, and all subsequent payments are due on the same day of each month there after. The final payment of principal and accrued interest was due on June 9, 2018. The note was paid in full during the nine months ended September 30, 2015.

7. BANK LINE OF CREDIT

The Company received an unsecured revolving line of credit from Wells Fargo Bank for $70,000, which as of September 30, 2015 has a zero balance. The interest rate is prime plus 4% payable every month.

The Company has a secured line of credit from National Bank of California for $350,000, which as of September 30, 2015 had a zero balance. The line of credit is secured by a personal guarantee and accounts receivable. The interest rate is 5.5% per annum and payable every month. The note was renewed in June 2015 and matures June 2016.

8. SUBSEQUENT EVENT

Management has evaluated subsequent events according to the requirements of ASC TOPIC 855, and has determined there are no subsequent events to be reported.

9. COMMITMENTS AND CONTINGENCIES

Commitments

Operating Leases

The Company's principal executive offices and its warehouse and distribution operations moved to 7251 Condor Street, Commerce California in March 2011. The Company leases 27,500 square feet at this location. The rental amount increased from $7,700 per month to $8,800 per month effective March 1, 2013. Approximately 2,500 square feet of the premises is used for executive offices, and the balance of the premises is used for warehouse and distribution operations. The lease is for a period of three years which commenced on March 1, 2011 and terminates on February 28, 2014. The Company has the option to extend the lease for two additional three year periods. If the Company exercises the first option to extend, the rental rate would increase to $9,900 per month effective March 1, 2014, $11,000 per month effective March 1, 2015 and $11,550 per month effective March 1, 2016. If the Company exercises the second option to extend, the rental rate would be adjusted to a fair market rental value as may be agreed to by the parties or as may be determined by an appraiser or arbitrator as provided in the Option to Extend Addendum. Payment of the lease has been personally guaranteed by Jack Amin and his wife, Nora Amin. The Company believes this space will be sufficient for at least the next twelve months.

The Company’s Dermagen, Inc. manufacturing operations are currently located at 2500 East Fender Avenue, Units I&J, Fullerton, California, which is leased under one lease agreement dated March 1, 2011. The Company leases approximately 3,520 square feet at a rental rate of $2,464 per month. The lease was initially for a period of one year which commenced on March 1, 2011. In early 2012, and again in early 2013, the parties executed Amendments to extend the lease term for one year. The lease will now expire on February 28, 2014. Payment of the lease has been personally guaranteed by Jack Amin. The Company believes this space will be sufficient for at least the next twelve months.

The Company believes that the various facilities covered by the leases described above will be sufficient for at least the next twelve months.

Item 4. BUSINESS SEGMENT INFORMATION

Beginning in 2005, the Company has operations in two segments of its business, namely: Distribution and Health and Beauty Products. Distribution consists of the wholesale pharmaceutical distribution and resale of brand and generic pharmaceutical products, over-the-counter drugs and non-drug products and health and beauty products. Health and Beauty Products consist of the manufacture and distribution of primarily health and beauty products.

Amexdrug Corporation is located at 7251 Condor Street, Commerce, California 90040. Its phone number is (323) 725-3100. Its fax number is (323)725-3133. Its website is www.amexdrug.com. Shares of Amexdrug common stock are traded on the OTC Bulletin Board under the symbol AXRX.OB. The President of Amexdrug has had experience working in the pharmaceutical industry for the past 30 years.

Amexdrug Corporation, through its wholly-owned subsidiaries, BioRx Pharmaceuticals, Inc., Allied Med, Inc., Dermagen, Inc. and Royal Health Care, Inc., is a pharmaceutical and cosmeceutical company specializing in the research and development, manufacturing and distribution of pharmaceutical drugs, cosmetics and distribution of prescription and over-the-counter drugs, private manufacturing and labeling and a quality control laboratory. At Amexdrug Corporation, it is our anticipation to give our clientele the opportunity to purchase cost effective products while attempting to maximize the return of investments to our shareholders.

Amexdrug Corporation distributes its products through its subsidiaries, BioRx Pharmaceuticals, Inc., Allied Med, Inc., Dermagen, Inc. and Royal Health Care, Inc. primarily to independent pharmacies and secondarily to small-sized pharmacy chains, alternative care facilities and other wholesalers and retailers in the state of California.

BioRx Pharmaceuticals, Inc. is a proud member of the National Association of Chain Drug Stores (NACDS). BioRx Pharmaceuticals, Inc. has developed fourteen unique innovative products in the industry under the name Sponix.

Our team of professionals fully pledges the effectiveness of our distinct products.

At this time, we have certain distribution channels with suppliers and customers whom we know and trust, such as Amazon, and hundreds of independent pharmacies. Of the estimated 100,000 retailers (drug stores and food mass), our goal is to have 20,000 stores carry our products in 2013.

References in this report to "we," "our," "us," the "company" and "Amexdrug" refer to Amexdrug Corporation and also to our subsidiaries, BioRx Pharmaceuticals, Inc., Allied Med, Inc., Dermagen, Inc. and Royal Health Care.

BioRx Pharmaceuticals

On November 8, 2004, Amexdrug formed a new subsidiary, BioRx Pharmaceuticals, Inc. as a Nevada corporation. BioRx Pharmaceuticals, Inc. sells pharmacy and laboratory supplies nationwide. BioRx Pharmaceuticals, Inc. is also committed to offer skin care and over the counter (OTC) products that are recommended with trust and faith by physicians, primarily podiatrists and dermatologists. The focus and mission of BioRx Pharmaceuticals, Inc. is to create, develop and manufacture products to help ease pain and restore and maintain the overall well-being of our customers. We strive for high performance and quality. Our commitment is to offer natural and OTC products that are recommended with confidence by doctors and pharmacists and that the customer can use with pleasure. Our compliance program is diligently followed through the Company. BioRx Pharmaceuticals, Inc. maintains high ethics for animal welfare and our products are never tested on animals. All products are made in the USA.

A total of fourteen innovative health and wellness products have been manufactured for sale by BioRx Pharmaceuticals, Inc. These over-the-counter and natural products are effective for treatment of fungus, arthritis, sun burn protection and for healthy feet and nails. BioRx Pharmaceuticals is planning to sell these products to national chain drugstores, sport chain stores, natural food markets and other mass markets. These products are being marketed under the name of Sponix, and are being sold under the name of BioRx Pharmaceuticals.

Allied Med, Inc.

On December 31, 2001, Amexdrug acquired all of the issued and outstanding common shares of Allied Med, Inc., an Oregon corporation, in a share exchange in a related party transaction.

Allied Med, Inc., was formed as an Oregon corporation in October 1997 to operate in the pharmaceutical wholesale business of selling a full line of brand name and generic pharmaceutical products, over-the-counter (OTC) drug and non-drug products and health and beauty products to independent and chain pharmacies, alternative care facilities and other wholesalers. At Allied Med our sincere interest is our customers' needs. Our competitive discount pricing allows our customers an advantage.

Amexdrug assumed the operations of Allied Med, and Amexdrug has been building on the wholesale pharmaceutical operations of Allied Med.

The accompanying financial information includes the operations of Allied Med for all periods presented and the operations of Amexdrug Corporation from April 25, 2000.

Dermagen, Inc.

Amexdrug completed its purchase of Dermagen, Inc. on October 7, 2005. Dermagen, Inc. is now an operating subsidiary of Amexdrug. The acquisition of Dermagen, Inc. is not considered to be an acquisition of a significant amount of assets which would require audited financial statements of Dermagen, Inc.

Dermagen, Inc. is a growing manufacturing company specializing in the manufacturing and distribution of certain pharmaceuticals and health and beauty products. Dermagen, Inc. has a U.S.-FDA registered and state FDA approved manufacturing facility licensed to develop high margin skin and novel health and beauty products for niche markets. Dermagen's competitive advantage is in its excellent product research and development.

Royal Health Care Company

In October 2003, Allied Med, Inc. acquired 100% of the assets of Royal Health Care Company. Royal Health Care Company is a health and beauty company which has sold specially manufactured facial and body creams, arthritic pain relief medications and an exclusive patented hair care product to pharmacies, beauty salons, beauty supply stores and other fine shops. Royal Health Care Company uses the highest quality ingredients for the finest quality products. Each product has been formulated with the essential ingredients and plant extracts to achieve optimum potential and quality. Royal Health Care Company products are manufactured by Dermagen, Inc. in an FDA approved manufacturing facility.

The Royal Health Care Company assets acquired include the "Royal Health Care Company" name, logo, and related trademarks, all formulas to products manufactured for sale under the Royal Health Care Company name, and the Royal Health Care Company list of customers. These intellectual property rights were acquired without cost from a company in which Jack Amin's wife is a principal shareholder. Mr. Amin is the CEO and Chairman of Amexdrug Corporation and Allied Med, Inc. Management believes this acquisition will provide the Company with an opportunity to increase the number of products sold by the Company, and expand the Company's customer base.

On October 28, 2004, Amexdrug formed a new subsidiary, Royal Health Care, Inc. as a Nevada corporation. Royal Health Care, Inc. was formed to manufacture and sell health and beauty products.

Lease Agreements

The Company's principal executive offices and its warehouse and distribution operations moved to 7251 Condor Street, Commerce California in March 2011. The Company leases 27,500 square feet at this location. The rental amount increased from $7,700 per month to $8,800 per month effective March 1, 2013. Approximately 2,500 square feet of the premises is used for executive offices, and the balance of the premises is used for warehouse and distribution operations. The lease is for a period of three years which commenced on March 1, 2011 and terminates on February 28, 2014. The Company has the option to extend the lease for two additional three year periods. If the Company exercises the first option to extend, the rental rate would increase to $9,900 per month effective March 1, 2014, $11,000 per month effective March 1, 2015 and $11,550 per month effective March 1, 2016. If the Company exercises the second option to extend, the rental rate would be adjusted to a fair market rental value as may be agreed to by the parties or as may be determined by an appraiser or arbitrator as provided in the Option to Extend Addendum. Payment of the lease has been personally guaranteed by Jack Amin and his wife, Nora Amin. The Company believes this space will be sufficient for at least the next twelve months.

The Company's Dermagen, Inc. manufacturing operations are currently located at 2500 East Fender Avenue, Units I&J, Fullerton, California, which is leased under one lease agreement dated March 1, 2011. The Company leases approximately 3,520 square feet at a rental rate of $2,464 per month. The lease is for one year which commenced on March 1, 2011. The parties executed Amendments to extend the lease term for one year. The lease will now expire on February 28, 2016. Payment of the lease has been personally guaranteed by Jack Amin. The Company believes this space will be sufficient for at least the next twelve months.

The Company believes that the various facilities covered by the leases described above will be sufficient for at least the next twelve months.

Business Segments

Since 2005, Amexdrug has had operations in two segments of its business, namely: Distribution and Health and Beauty Products. Distribution consists of the wholesale pharmaceutical distribution and resale of brand and generic pharmaceutical products, over-the-counter drugs and non-drug products and health and beauty products. Health and Beauty Products consist of the manufacture and distribution of primarily health and beauty products. Manufacturing includes expertise in research and development for health care industry products, including pharmacy supplies.

Item 5. Identification of directors and executive officers

Name	Title	Number of shares Beneficially Owned	Percent of Class
Jack Amin 7251 Condor Street Commerce, CA 90040	President, Secretary, Treasurer and Director	155,184,040	91.7%
Rodney S. Baron, MD	Director	0	0.0%
Behrooz Meimand	Director	0	0.0%

Item 6. Legal Proceedings

To the best of Amexdrug's knowledge, no governmental authority is contemplating the filing of any material legal proceeding against the Company or its officers and directors.

Legal Counsel
Robert Wilkinson
136 E. South Temple #2400
Salt Lake City, UT 84111
(801) 533-9645

Anthony E. Bell
515 S. Flower Street, 36th Floor
Los Angeles, CA 90071
(213) 973-1288

Auditor
HJ & Associates, LLC
50 West Broadway, Suite 600
Salt Lake City, UT 84101
(801) 328-4408

Accountant
G&L Professional Services
2200 Outlet Center Drive, Suite 455
Oxnard, CA 93036
(805) 983-3369

Certifications of Chief Executive Officer and Chief Financial Officer

I, Jack Amin, certify that:

1. I have reviewed this interim report disclosure of Amexdrug Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: October 15, 2015 _/s/ Jack Amin_____
Jack Amin, Chief Financial Officer